Objectives Cancer is a leading cause of death. At end-of-life healthcare utilisation and expenditure peak. Understanding care patterns and quantifying the likely benefits from service reconfigurations may influence rates of hospital admission and deaths. Methods Using prevalence-based retrospective data from the Northern Ireland General Registrar’s Office linked by cancer diagnosis to Patient Administration episode data for unscheduled-emergency-care (1stJanuary 2014 to 31st December 2015), we estimate unscheduled-emergency-care costs in the last year of life and hypothetical resources released by reductions in length-of-stay for cancer patients who died in 2015. Linear regression examined patient characteristics affecting length-of-stay. Results 3134 cancer patients used 60,746 days of unscheduled-emergency-care (average 19.5 days). Of these, 48.9% had ≥1 admission during their last 28 days of life. Total estimated cost was £28,684,261, averaging £9,200 per person. Lung cancer patients had the highest proportion of admissions (23.2%, mean length-of-stay = 17.9 days, mean cost=£7,224). Highest service use and total cost was in those diagnosed at Stage IV (38.4%), required 22,099 days of care, costing £9,629,014. Palliative care support, identified in 25.5% of patients, contributed £1,322,328. A 3-day reduction in mean length-of-stay with a 10% reduction in admissions, could reduce costs by £7.37 million. Regression analyses explained 41% of length-of-stay variability. Conclusions The cost burden from unscheduled care use in the last year of life of cancer patients is significant. Opportunities to prioritise service reconfiguration for high-costing users emphasized lung and colorectal cancers offering the greatest potential to influence outcomes.
No takes yet. Share an insight, caveat, or question.
McFerran et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: